Drug development

#Drug development #Drug innovation #Funding #Investment

CatSci secures £4.5 million funding deal for drug development 

CatSci, a partner for medicines development, has secured £4.5 million of investment to expedite the development and launch of what it calls its life-changing therapeutics.  The company develops economically and environmentally sustainable drug manufacturing processes that enable its global pharmaceutical customers to create affordable small molecule therapeutics… Read More

#News

#Drug development #Drug discovery #Pharma

Target product profiles and strategies for drug development

Hettie Stroebel, Founder and CEO of Launch Excellence looks at how target product profiles can be used by life sciences companies as a strategy for more effective product development.    The global effort to develop and distribute a SARS-CoV-2 vaccine in months is a triumph for the pharmaceutical industry. It is… Read More

#News #Opinion

#Biopharmaceuticals #Biotherapeutics #Drug development

Successful discovery and development collaboration continues  

Thermo Fisher Scientific and Symphogen are continuing their collaboration to provide biopharmaceutical discovery and development laboratories with innovative tools and streamlined workflows for efficient characterisation of complex therapeutic proteins.   Since the collaboration began in 2018, Symphogen has adopted instruments and software to improve data quality and processes… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Events #Medtech #Public health

Life Science community gathers in London for key partnering event 

For the last seven years, the LSX World Congress has bought together biotech, medtech and healthtech executives to connect with the capital, intelligence, innovation, and partners they need to grow their businesses. Back in-person for 2022, the 8th Congress takes place 10-11 May at 133 Houndsditch in London. … Read More

#News #Trending News

#Antimicrobials #Bioconvergence #Drug development #Immunology / Virology & Vaccines #mRNA

Bioconvergence: Future trends for biomedicine

Dr. Tom Knapman, Director of Strategic Brand at SCIEX, explains how bioconvergent advances will help to drive key health trends in the coming year. As we move into 2022, we will see more and more advances in bioconvergence – biological, physical, and computing technologies inspired by nature. We expect these… Read More

#Exclusive Content #News #Opinion #Trending News #Trends & Analysis

#Drug development #Drug discovery #Drug research #Pharmaceutical #Zebrafish

Appointment to help bridge the gap between isolated systems

The MDI Biological Laboratory (MDIBL) has appointed James Strickland as Director of MDI Bioscience, a new initiative focused on using non-mammalian models in early drug discovery and development.   Background  Strickland brings experience in pharmaceutical development to his new position, in which he will leverage… Read More

#News

#Biopharmaceuticals #Drug development #Drug innovation #Funding

Key take-aways from new R&D trends report 

As the global Covid-19 pandemic enters its third year, the life sciences innovation system is setting new records in the level of investment, activity, and scientific progress, according to the IQVIA Institute. In its report, Global Trends in R&D: Overview through 2021, the IQVIA assesses the trends… Read More

#News #Trends & Analysis

#CRO #Drug development #Drug discovery #Genomics

CROs: Drug discovery expertise on hand  

Listen to this article on the DDW Podcast: Lu Rahman asks Laura Hinton, Operations Director at Gentronix, to offer some insight into the contract research organisation (CRO) market and how Gentronix is making its presence known in this sector.  Gentronix is a specialist contract research organisation (CRO) based in the UK, focused on delivering… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

Bacteria
#Drug development #Drug discovery #Events #Microbiome #Therapeutics

Take aways from Microba’s presentation at European summit

Microba Life Sciences, a precision microbiome science company based in Australia, showcased its therapeutic platform and discovery platform for the identification of novel microbial signatures at Microbiome Movement, a European drug development summit, on January 27.  The event  The event brought together researchers from the biopharmaceutical… Read More

#News

#Biotechnology #Clinical trials #Drug development #Tumours

Avacta takes step to increase the tolerability of chemotherapies  

Avacta has added the next pre|CISION drug candidate to its portfolio. AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023.  The technology  Avacta’s chemistry is used to modify chemotherapy drugs to render them inactive… Read More

#News

#Antibiotics #Drug development #Funding #Research

US researcher awarded $3.6 million to study antibiotic resistance

Sanford Burnham Prebys professor Andrei Osterman, Ph.D., has been awarded a $3.6 million grant from the National Institutes of Health (NIH) to expand current knowledge of antibiotic resistance, which will inform more precise antibiotic prescribing practices and help researchers develop drugs that are harder for bacteria to resist.   Context… Read More

#News

#Comment #Covid-19 #Drug development #Drug discovery

From the editor: Courage and curiosity in collaboration 

Collaboration within the drug discovery sector is well documented, says Lu Rahman. During the Covid-19 pandemic we have seen great examples. Take Pfizer and BioNTech or the work between Carterra and Eli Lilly Company to create bamlanivimab, a Covid-19 therapeutic. Collaborative work has created vaccines and therapeutics which are… Read More

#Editor's Choice #News #Opinion

#Cancer research #Clinical trials #Drug development #Molecular research #Oncology #Personalised medicine

Exclusive: The personalised medicine paradigm

Since the turn of the century, when the term “personalised medicine” was first coined, the use of molecular diagnostic (or biomarker) testing in clinical trials has continued to grow in terms of complexity and importance. These tests have undergone a period of rapid development and growth in the last decade, with the implementation… Read More

#Editor's Choice #Exclusive Content #News

#AI #Collaboration #Drug development #Drug discovery

Exscientia and Sanofi to develop AI-driven medicines 

Sanofi and Exscientia have announced a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilising actual patient samples.   Background  The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia’s novel bispecific small… Read More

#News

#Collaboration #Drug development #Immunology / Virology & Vaccines #mRNA

Pfizer and BioNTech develop first mRNA-based shingles vaccine

Pfizer and BioNTech have announced a new research, development and commercialisation collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV), which impacts about one in three people in the US during their lifetime.   Why now?  The collaboration… Read More

#News

#Drug development #Partnership

Quebecian acquisition expands preclinical platform 

Altasciences, an integrated CRO/CDMO offering solutions to early-stage drug development, has completed the acquisition of Sinclair Research, a preclinical CRO located in the Midwest (US). The new site will facilitate access to Altasciences’ preclinical services across the US.  “This acquisition will add significant capacity and expertise to Altasciences’ existing… Read More

#News